Crossref journal-article
Elsevier BV
Cancer Cell (78)
Bibliography

Stojdl, D. F., Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., Brown, E. G., Durbin, R. K., Durbin, J. E., Hiscott, J., & Bell, J. C. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell, 4(4), 263–275.

Authors 15
  1. David F Stojdl (first)
  2. Brian D Lichty (additional)
  3. Benjamin R tenOever (additional)
  4. Jennifer M Paterson (additional)
  5. Anthony T Power (additional)
  6. Shane Knowles (additional)
  7. Ricardo Marius (additional)
  8. Jennifer Reynard (additional)
  9. Laurent Poliquin (additional)
  10. Harold Atkins (additional)
  11. Earl G Brown (additional)
  12. Russell K Durbin (additional)
  13. Joan E Durbin (additional)
  14. John Hiscott (additional)
  15. John C Bell (additional)
References 52 Referenced 693
  1. 10.1128/JVI.77.8.4646-4657.2003 / J. Virol. / Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis by Ahmed (2003)
  2. 10.1080/713803696 / IUBMB Life / Vesicular stomatitis virus (VSV) therapy of tumors by Balachandran (2000)
  3. 10.1016/S1074-7613(00)00014-5 / Immunity / Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection by Balachandran (2000)
  4. 10.1084/jem.20011666 / J. Exp. Med. / Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo by Barchet (2002)
  5. 10.2174/1566523024605582 / Curr. Gene Ther. / Oncolytic viruses by Bell (2002)
  6. 10.1016/0165-4608(94)90195-3 / Cancer Genet. Cytogenet. / Molecular analysis of genomic abnormalities in human gliomas by Bello (1994)
  7. 10.1128/JVI.64.4.1716-1725.1990 / J. Virol. / Role of matrix protein in cytopathogenesis of vesicular stomatitis virus by Blondel (1990)
  8. 10.1099/0022-1317-71-4-991 / J. Gen. Virol. / Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus by Coulon (1990)
  9. 10.1016/S0168-1702(01)00251-9 / Virus Res. / Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells by Desforges (2001)
  10. 10.1038/41493 / Nature / A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB by DiDonato (1997)
  11. 10.1128/JVI.71.1.371-377.1997 / J. Virol. / The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter by Ferran (1997)
  12. 10.1016/0042-6822(87)90065-1 / Virology / The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis by Francoeur (1987)
  13. 10.4049/jimmunol.164.10.5352 / J. Immunol. / Regulation of RANTES chemokine gene expression requires cooperativity between NF-kappa B and IFN-regulatory factor transcription factors by Genin (2000)
  14. {'key': '10.1016/S1535-6108(03)00241-1_BIB14', 'first-page': '503', 'article-title': 'Viruses for the treatment of malignant glioma', 'volume': '3', 'author': 'Gromeier', 'year': '2001', 'journal-title': 'Curr. Opin. Mol. Ther.'} / Curr. Opin. Mol. Ther. / Viruses for the treatment of malignant glioma by Gromeier (2001)
  15. 10.1016/S1470-2045(01)00618-0 / Lancet Oncol. / Oncolytic biotherapy by Hawkins (2002)
  16. 10.1126/science.276.5320.1845 / Science / Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus by Her (1997)
  17. 10.1038/ng1080 / Nat. Genet. / Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery by Hieronymus (2003)
  18. 10.1128/JVI.67.11.6698-6706.1993 / J. Virol. / Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice by Huneycutt (1993)
  19. 10.1128/JVI.74.10.4765-4775.2000 / J. Virol. / Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant by Ikeda (2000)
  20. 10.1128/JVI.74.21.9818-9827.2000 / J. Virol. / Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release by Jayakar (2000)
  21. 10.1016/0960-7404(92)90072-S / Surg. Oncol. / Intra-rectal injection of tumour cells by Kashtan (1992)
  22. 10.1089/10430340252809784 / Hum. Gene Ther. / Toward a new generation of conditionally replicating adenoviruses by Kruyt (2002)
  23. 10.1073/pnas.92.10.4477 / Proc. Natl. Acad. Sci. USA / Recombinant vesicular stomatitis viruses from DNA by Lawson (1995)
  24. 10.1084/jem.20020075 / J. Exp. Med. / Whence interferon? Variety in the production of interferon in response to viral infection by Levy (2002)
  25. 10.1074/jbc.M002814200 / J. Biol. Chem. / Multiple regulatory domains control IRF-7 activity in response to virus infection by Lin (2000)
  26. {'key': '10.1016/S1535-6108(03)00241-1_BIB26', 'first-page': '4099', 'article-title': 'Interferon system defects in human malignant melanoma', 'volume': '55', 'author': 'Linge', 'year': '1995', 'journal-title': 'Cancer Res.'} / Cancer Res. / Interferon system defects in human malignant melanoma by Linge (1995)
  27. 10.1074/jbc.M005288200 / J. Biol. Chem. / Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon and silencing by hypermethylation by Lu (2000)
  28. 10.1006/viro.1996.0585 / Virology / Potency of wild-type and temperature-sensitive vesicular stomatitis virus matrix protein in the inhibition of host-directed gene expression by Lyles (1996)
  29. {'key': '10.1016/S1535-6108(03)00241-1_BIB29', 'first-page': '2261', 'article-title': 'Impaired alpha-interferon signaling in transitional cell carcinoma', 'volume': '61', 'author': 'Matin', 'year': '2001', 'journal-title': 'Cancer Res.'} / Cancer Res. / Impaired alpha-interferon signaling in transitional cell carcinoma by Matin (2001)
  30. 10.1006/jmbi.2001.5401 / J. Mol. Biol. / Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription by Morin (2002)
  31. 10.1006/bbrc.2001.4913 / Biochem. Biophys. Res. Commun. / Gene induction pathways mediated by distinct IRFs during viral infection by Nakaya (2001)
  32. 10.1128/JVI.41.3.1055-1062.1982 / J. Virol. / In vitro reassembly of vesicular stomatitis virus skeletons by Newcomb (1982)
  33. 10.1016/S1359-6101(00)00024-1 / Cytokine Growth Factor Rev. / Oncolytic viruses and cancer therapy by Norman (2001)
  34. 10.1128/JVI.70.9.6414-6417.1996 / J. Virol. / Large-population passages of vesicular stomatitis virus in interferon-treated cells select variants of only limited resistance by Novella (1996)
  35. 10.1128/MCB.20.22.8590-8601.2000 / Mol. Cell. Biol. / The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes by Petersen (2000)
  36. 10.1016/S0014-5793(98)01514-2 / FEBS Lett. / Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7 by Sato (1998)
  37. 10.1016/S0014-5793(98)00210-5 / FEBS Lett. / Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene by Sato (1998)
  38. 10.1126/science.1081315 / Science / Triggering the interferon antiviral response through an IKK-related pathway by Sharma (2003)
  39. 10.1084/jem.186.8.1213 / J. Exp. Med. / Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases by Specht (1997)
  40. 10.1128/JVI.69.4.2153-2158.1995 / J. Virol. / Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice by Steinhoff (1995)
  41. 10.1128/JVI.74.20.9580-9585.2000 / J. Virol. / The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus by Stojdl (2000)
  42. 10.1038/77558 / Nat. Med. / Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus by Stojdl (2000)
  43. 10.1182/blood.V91.2.570 / Blood / Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression by Sun (1998)
  44. 10.4049/jimmunol.167.9.5209 / J. Immunol. / The vesicular stomatitis virus matrix protein inhibits glycoprotein 130-dependent STAT activation by Terstegen (2001)
  45. 10.1016/S1097-2765(00)00120-9 / Mol. Cell / Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98 by von Kobbe (2000)
  46. 10.1006/mthe.2002.0547 / Mol. Ther. / The complement response against an oncolytic virus is species-specific in its activation pathways by Wakimoto (2002)
  47. 10.1038/sj.gt.3302038 / Gene Ther. / Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells by Wakimoto (2003)
  48. 10.1016/S1097-2765(00)80051-9 / Mol. Cell / Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo by Wathelet (1998)
  49. {'key': '10.1016/S1535-6108(03)00241-1_BIB49', 'first-page': '1317', 'article-title': 'Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment', 'volume': '63', 'author': 'Wein', 'year': '2003', 'journal-title': 'Cancer Res.'} / Cancer Res. / Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment by Wein (2003)
  50. 10.1074/jbc.272.45.28779 / J. Biol. Chem. / Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma by Wong (1997)
  51. 10.1038/sj.cgt.7700345 / Cancer Gene Ther. / Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice by Yoon (2001)
  52. 10.1128/JVI.75.9.4453-4458.2001 / J. Virol. / Inhibition of host transcription by vesicular stomatitis virus involves a novel mechanism that is independent of phosphorylation of TATA-binding protein (TBP) or association of TBP with TBP-associated factor subunits by Yuan (2001)
Dates
Type When
Created 21 years, 4 months ago (April 14, 2004, 5:27 a.m.)
Deposited 5 years, 5 months ago (March 31, 2020, 8:04 p.m.)
Indexed 1 week, 3 days ago (Aug. 26, 2025, 2:50 a.m.)
Issued 21 years, 11 months ago (Oct. 1, 2003)
Published 21 years, 11 months ago (Oct. 1, 2003)
Published Print 21 years, 11 months ago (Oct. 1, 2003)
Funders 0

None

@article{Stojdl_2003, title={VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents}, volume={4}, ISSN={1535-6108}, url={http://dx.doi.org/10.1016/s1535-6108(03)00241-1}, DOI={10.1016/s1535-6108(03)00241-1}, number={4}, journal={Cancer Cell}, publisher={Elsevier BV}, author={Stojdl, David F and Lichty, Brian D and tenOever, Benjamin R and Paterson, Jennifer M and Power, Anthony T and Knowles, Shane and Marius, Ricardo and Reynard, Jennifer and Poliquin, Laurent and Atkins, Harold and Brown, Earl G and Durbin, Russell K and Durbin, Joan E and Hiscott, John and Bell, John C}, year={2003}, month=oct, pages={263–275} }